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Abstract 
Purpose: Drug safety classifications give a very basic estimation of risk and should only be 
used as general guideline when assessing risk of pregnancy-related drug exposure or 
planning treatment. We conducted a study to assess the strength of association between 
both the clinical pharmacologists’ risk assessment and the FDA risk categorization, and 
adverse pregnancy outcomes.  Methods: We retrospectively reviewed records of 1076 
patients consecutively referred to the clinical pharmacology outpatient clinic for pregnancy-
related drug exposures (2000-2008). Clinical pharmacologists’ risk assessments were 
reviewed in relation to FDA drug categorization and available pregnancy outcomes. Results: 
Overall, clinical pharmacologists’ risk estimation was in agreement with the FDA risk 
categorization system in only 28% of consulted women, and in only 9% of women with high 
risk exposure (FDA DX). Clinical pharmacologists’ risk assessment confirming high risk drug 
exposure had a better positive predictive value for adverse pregnancy outcomes than the 
FDA DX categorization (25% vs. 14%, respectively), while the negative predictive values 
were similar (92% vs. 94%, respectively). Clinical pharmacologists’ risk assessment was a 
better predictor of adverse pregnancy outcomes when compared to FDA risk categorization 
[OR 2.11 (95%CI 1.5-3.1; p<0.001) vs. OR 1.52 (95%CI 1.1-2.1; p=0.014), respectively]. 
Conclusions: Additional evaluation beyond the FDA drug classification is essential for safer 
and more rational drug use in pregnancy. Clinical pharmacologists who have undergone 
rigorous medical training are ideally placed to consult on administration of medicines in 
pregnant women, thus making the prescribing of treatments in that patient category 
substantially safer and more rational.   
 
Key words: pregnancy-related drug exposure, FDA, drug safety classifications, clinical 
pharmacology, risk assessment, drug safety 
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Introduction 
The estimated prevalence of birth defects in general population is 2-4% [1]. It is claimed that 
this prevalence is mainly independent of drug use in pregnancy, with less than 1% of birth 
defects thought to be attributable to maternal drug use [2]. Nevertheless, there is much fear 
about prescribing drugs in pregnant women, making underprescribing as much a concern as 
overprescribing. Several studies have explored the prevalence of drug prescription in 
pregnant women, with a wide range of results from 19% to more than 90% of pregnant 
women receiving at least 1 drug during pregnancy [3-6]. As approximately 50% of 
pregnancies are unplanned, often drug exposure occurs in the early and most vulnerable 
stage of pregnancy [7].  Therefore, risk classification systems have been set up to 
summarise the available data on drug safety during pregnancy and to help in assessment of 
risks of pregnancy-related drug exposures and balancing of benefits and risks when 
prescribing drugs in pregnant women. One of the most frequently used is the US Food and 
Drug Administration (FDA) pregnancy risk categorisation which places the drug in one of five 
categories (A, B, C, D and X) according to the level of risk to the infant [8]. However, it is 
important to understand that drug safety classifications give a very basic estimation of risk 
and should only be used as general guidelines when planning treatment [9], and that there 
are inconsistencies between various drug classifications which can be a source of great 
confusion among users of drug safety classification systems [10]. Although the FDA has 
announced the replacement of the present risk classification system with a narrative 
framework in order to ease informed counselling on drug safety in pregnancy, the pregnancy 
risk categories are still in effect and are still being used by physicians [11]. Since Croatia has 
not established its own risk classification system, the FDA risk classification system is still the 
most used system in Croatia, due to its accessibility to prescribers through the Croatian Drug 
Registry [12] and the Croatian Pharmacotherapeutic Formulary [13].   
However, risk assessments must always be made on an individual basis, and the dose, 
route, duration, and gestational timing of the exposure must also be taken into consideration 
in each case.  Both underestimation and overestimation of risk must be avoided, and 
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pregnant women with conditions requiring treatment must be treated adequately. Although 
their medical training predisposes clinical pharmacologists to a significant role in the area of 
drug use during pregnancy, this is probably the least developed area of clinical 
pharmacology.  
There is lack of organized information services on drug safety during pregnancy in Croatia; 
information is mostly available through some hospital Departments of Paediatrics, 
Gtynaecology or Clinical Pharmacology. There is only one office in Croatia (Genetic 
Counselling with Teratogen Information Service) that is a part of European Network of 
Teratology Information Services (ENTIS), which includes 12 European and 2 non-European 
countries with the objective to coordinate the activities of different Teratology Information 
Services [14]. Similarly, councelling of patients and health care providers about exposures 
related to pregnancy and breastfeeding in North America is provided through the  
Organization of Teratology Information Services (OTIS) [15].  
Consultations on drug use during pregnancy have a 20-year tradition at our unit. When 
consulting women on risks of drug exposure or therapy planning during pregnancy, we too 
use the FDA risk categorization system as well as the Australian Drug Evaluation 
Committee's categorization [16]; however, only as a general guidance. To the best of our 
knowledge, there are no studies that examine the proportion of agreement between a 
classification system and a clinical pharmacologist’s (or other experts’) risk assessment on 
pregnancy-related drug exposure which also includes the evaluation of these differences in 
relation to pregnancy outcomes. In one study that similarly compared the differences in 
advice on drug safety in pregnancy between product monographs and Drug Information 
Centres in Norway, no data on pregnancy outcomes were available [17].   
With these objectives in mind we conducted this study hoping to provide a clearer 
assessment of value of the FDA risk classification and clinical pharmacologists’ consultation 
in relation to adverse pregnancy outcomes caused by medication use.  
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Methods 
Study Design and Patient Population 
The Division of Clinical Pharmacology at the University Hospital Zagreb comprises a ward 
(11 beds), clinical research unit and outpatient clinic. The clinical pharmacology outpatient 
clinic serves patients with various pharmacotherapeutical problems. Approximately 20% of 
patients at the outpatient clinic are referred for consultation on drug use in pregnancy. During 
the first patients’ visit, demographic data, data on concomitant diseases, reasons for referral, 
habits (smoking, alcohol consumption), previous pregnancies, prescribed medications and 
indications for their prescription, are collected by the use of a structured questionnaire. For 
every patient advised, a written clinical pharmacologist’s expert opinion is prepared with a 
risk estimation concerning the individual patient’s characteristics and indications for drug 
treatment, and sent by post within 2-3 days to the referring physician or/and the patient’s 
home address (when requested). Where appropriate, a final risk assessment is made with 
recommendations for the continuation, reassessment or discontinuation of therapy. 
Approximately 9-12 months after the consultation counselled patients are contacted by 
phone or post (where telephone number was not available) in order to obtain information on 
the pregnancy outcomes.  
We retrospectively reviewed records of 1144 consecutively referred patients during a 9-year 
period (2000-2008). Clinical pharmacologists’ risk assessments of patients were reviewed in 
relation to the FDA drug categorization and available pregnancy outcomes. This study 
included only patients referred for consultation on pregnancy-related drug exposures. 
Pregnancy outcomes were available for 516 patients. Prior to data analysis of adverse 
pregnancy outcomes, we excluded cases of induced abortions (46 cases) and exposures to 
medications not classified by FDA risk classification system (5 cases); 465 pregnancy 
outcomes were available for further analysis. Adverse pregnancy outcomes included were: 
spontaneous abortion, malformations, and other complications during pregnancy (preterm 
birth, perinatal complications possibly related to medication use).  
FDA pregnancy risk classification and risk assessment 
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All drugs prescribed to a patient during pregnancy were classified according to the FDA risk 
classification. Since the FDA categorization scheme classifies drugs in one of five major 
categories according to the potential fetal risk (A, B, C, D and X), we converted it into a 
numeric rating scale (NRS; 1, 2, 3, 4 and 5). Similarly, final clinical pharmacologists’ risk 
assessments were also converted into the same numeric scale thus allowing further 
comparisons and analysis (Table 1). Literature data on the use of specific drugs during 
pregnancy, gestational age of the embryo or fetus during the exposition to the drug, route of 
drug administration, absorption rate of the drug, whether the drug crosses the placenta, 
indication for the treatment, etc., were taken into account for each patient prior to final risk 
assessment. In compiling the clinical pharmacologists’ expert opinion following sources were 
used: British National Formulary [18], AHFS Drug Information [19], Briggs’ Drugs in 
pregnancy and lactation [20], Micromedex Database [21], PubMed [22] search on latest 
articles published on specific topic.  The FDA and ADEC categorization are used as a 
general guideline, which was followed by extensive literature search on drug safety of a 
specific drug, with the remark that all clinical pharmacologists working as consultants have 
more than 5 years experience in the area of drug safety in pregnancy and have in-depth 
knowledge in this field of clinical pharmacology.  
Statistical Methods 
Standard descriptive statistics were used to describe the study population, referral 
characteristics and pregnancy exposures. Means and Standard Deviations (SD) were 
calculated for continuous variables. For categorical data proportions were calculated and 
analyzed using the M-L Chi-square test. Statistical significance was set at p<0.05.  
Associations with adverse pregnancy outcomes for FDA categorization and clinical 
pharmacologists’ risk assessment (on a NRS), age, parity, number of spontaneous abortions, 
and number of prescribed drugs were evaluated using multiple logistic regression for 
continuous predictors, with adjusted odds ratios and its 95% confidence intervals as the 
association measures, or where appropriate (for categorical variables: smoking, age group, 
previous pregnancies, and previous history of spontaneous abortions) by calculating odds 
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ratios and its 95% confidence intervals for a 2x2 contingency table, using Chi-square test of 
association. Positive and negative predictive values for adverse pregnancy outcomes were 
calculated for both FDA DX (NRS 4 and 5) categorization and clinical pharmacologists 
categorization (NRS 4 and 5).  
All tabulations and statistical analysis were done using Statistica for Windows, Version 8.0, 
StatSoft, Inc. (2008).
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Results 
Between 2000 and 2008, we advised 1144 pregnant women, aged 16-47 years (mean age 
30 years) referred to the clinical pharmacology outpatient clinic for consultations on 2244 
drug exposures and 81 radiological diagnostic procedures.  
Most consultations were regarding drug exposure during pregnancy (95%); other 
consultations included therapy planning during this or future pregnancies, partners’ drug 
exposure, diagnostic procedures, and other exposure-related problems during pregnancy.  
For the purpose of this study, we further analyzed only data on patients referred for 
consultations on pregnancy-related drug exposure (N=1076). Patients were mostly referred 
due to drug exposure during the 1st trimester of pregnancy (95%) and 84% of them were 
advised in their 2nd month of pregnancy.  
Most of the women were referred by a gynaecologist (89%), followed by general physicians 
(5%) and other specialists (4%; mostly neurologists and psychiatrists), and 2% of patients 
came self-initiatively. 
Similar proportions of patients were consulted on drugs prescribed for the treatment of an 
acute condition (45%) and a chronic condition (41%). The mean number of drugs taken 
during pregnancy was 2.1 (range 1-9), and more than 50% of women were prescribed ≥2 
drugs. For more than 40% women this was their first pregnancy. The patients’ demographic 
and referral characteristics are shown in Table 2.   
Drug exposure and risk assessment 
When exposure to individual drugs was taken into account most women were exposed to 
FDA category C (56%) and category B drugs (41%). When the highest FDA drug category 
among drugs prescribed to an individual patient was taken into account, most women were 
exposed to at least FDA category C (39%), followed by category D (30%) drugs. The 
exposure to high risk FDA drugs (FDA DX) drugs was high; 34% (466 women) of pregnant 
women were prescribed at least one FDA category D or X drug. When the FDA 
categorization system was converted to a numeric scale (NRS 1-5), the mean risk 
assessment value in the studied population was 3.4 (Std.Dev. ± 0.96). Fifty-seven women 
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(5.4%) were exposed to medications with unknown pregnancy categories. Data on 
pregnancy-related drug exposure are summarized in Table 2.  
The clinical pharmacologists’ risk assessment was available for all patients consulted on 
drug exposure during pregnancy. Estimation of high risk exposure was recorded for 95 
women (9%). On a numeric rating scale, the mean risk assessment value was 2.3 (Std.Dev. 
±0.71).  
Clinical pharmacologists’ risk assessment was agreeable with FDA risk categorization in only 
17% of FDA D drug exposures and 14% of FDA X drug exposures. In all other cases the 
clinical pharmacologists’ risk assessment was lower; with the highest mean point difference 
of 2.2 within the FDA X group (Table 3).  
Clinical pharmacologists’ risk assessment vs. FDA classification in regard to available 
pregnancy outcomes 
Due to the high rate of patients lost for follow-up, pregnancy outcomes were available only 
for 516 pregnancies (48%). Starting in 2004, we more thoroughly organized the collection of 
follow-up data of advised patients using a more active approach (repeated phone calls and 
search for potentially changed phone numbers or address in case of failure, etc). The most 
patients that were lost to follow-up were advised in the previous period, and were lost to 
follow-up due to the lack of information on, or changes in, patient’s phone numbers, home 
address, etc.  
There were no significant differences in age, referring physician, previous pregnancy, parity, 
history of spontaneous or induced abortions, number of prescribed drugs, FDA’s and clinical 
pharmacologists’ risk classification, between women with available outcomes and women 
that were lost to follow-up. The only confounder that was more present in the group of 
women with available pregnancy outcomes was smoking (30% vs. 23%; p=0.012, 
respectively). Nevertheless, we conclude that women with available pregnancy outcomes are 
representative for the whole sample of 1076 patients advised on pregnancy-related drug 
exposure 
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Four hundred and thirty-five healthy babies were delivered in 428 pregnancies, there were 46 
cases of induced abortions, and 31 cases of spontaneous abortions, 8 women suffered other 
complications during pregnancy and there were 3 cases of observed congenital 
malformations (1 major, 2 minor). After excluding induced abortions (46 cases) and 
exposures to medications not classified by the FDA (5 cases), 465 pregnancy outcomes 
were available for further analysis. We did not include cases of induced abortions, since they 
do not represent adverse pregnancy outcomes in the narrow sense, i.e. adverse outcome 
directly attributable to the use of a medication.  
Both FDA and clinical pharmacologists’ risk classification were revealed as significant 
predictors for adverse pregnancy outcomes. However, calculation of odds ratios (OR) 
confirmed a more significant association of clinical pharmacologists’ risk assessment as 
compared to FDA risk categorization, both when using a NRS or proportions of those 
exposed to high risk medications (Table 4). Clinical pharmacologists’ categorization of 
pregnancy-related drug exposure to a high risk group (NRS 4 and 5), had a better positive 
predictive value for adverse pregnancy outcomes as compared to the FDA categorization 
(25% vs. 14%, respectively), while the negative predictive values were similar (92% vs. 94%, 
respectively). Overall, clinical pharmacologists’ risk estimation for studied drug exposures 
was lower as compared to the FDA risk categorization. 
Other risk factors associated with adverse pregnancy outcomes 
Clinical pharmacologists’ risk assessment was the strongest predictor of adverse pregnancy 
outcomes, whereas the number of drug exposition was not significantly related to adverse 
pregnancy outcomes. Other risk factors significantly associated with adverse pregnancy 
outcomes were age, concomitant diseases, previous pregnancies, and parity. Cigarette 
smoking and number of drug exposures were not significantly associated with adverse 
pregnancy outcomes. Although the history of previous spontaneous abortions was not 
significantly related to adverse pregnancy outcomes, the number of previous spontaneous 
abortions increased the odds for an adverse pregnancy outcome. The calculated ORs for all 
evaluated risk factors and their confidence intervals are shown in Table 4.  
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Discussion 
This study confirms significant differences in risk estimation between the FDA classification 
system and the clinical pharmacologists’ risk assessment for pregnancy-related drug 
exposures, with an overall agreement in only 28% of cases.  
The FDA categorization system gives only limited guidance to the prescribing physician, and 
many clinicians feel that despite the intent of the new labelling requirements to facilitate drug 
prescribing for pregnant patients, it has not lived up to original expectation in this regard [9]. 
It has been claimed that the FDA system is too simple and exerts confusion concerning 
gradation of risk across the categories. The second criticism of these categories is that they 
create an incorrect impression that the drugs within a given category present similar 
reproductive risk. Among the drugs listed in the Physicians' Drug Reference, only 0.7% of 
drugs carry an FDA category A classification; 19% are in category B; 66% are in category C; 
7% are in category D and 7% are in category X [23]. In response to these objections, the 
FDA made an announcement in May 2008, stating that they will replace the current A, B, C, 
D, and X classification system with a narrative framework consisting of 3 major information 
parts: risk summary, clinical consideration and data. These changes were designed to 
facilitate informed counselling about and prescribing of medicines for women who are 
pregnant, breastfeeding, or of childbearing potential [11]. However, to date, the pregnancy 
risk categories are still in effect and are still being used by physicians.  
 Whether to prescribe a drug to a pregnant woman is a decision that must be made on an 
individual basis and includes a critical assessment of the available data from studies done in 
animals and humans. Furthermore, there are numerous factors that should be taken into 
consideration: gestational age of the embryo or fetus during the exposition to the drug, route 
of drug administration, pharmacokinetic and pharmacodynamic characteristics of the drug 
[24].   
The evaluation of population characteristics in our study revealed a population under 
increased basal risk for adverse pregnancy outcomes, mainly due to the increased age, high 
prevalence of chronic conditions and exposure to high-risk drugs (FDA DX). The mean 
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number of drugs prescribed to pregnant women in our study was similar or even lower than 
in studies exploring drug use during pregnancy [25] and comparable to a cross-sectional 
study that evaluated the drug use in pregnant women of 4 Zagreb’s maternity hospitals 
(mean 2.6 drugs) [26]. However, the exposure of pregnant women included in our study to 
FDA category DX drugs was significantly higher when compared with the exposure in 
general population of pregnant women (34% vs. approximately 6-7%) [6,27]. These findings 
were not surprising, and could be attributable to the tendency of other specialists to refer 
patients exposed to high risk drugs to a clinical pharmacologist for further consultations, 
while patients exposed to drugs carrying lower risk categories are consulted within their own 
clinics. The prevalence of other risk factors was as well considerable within the studied 
population; 51% of pregnant women were older than 30 years and 52% were suffering from a 
chronic condition. The percentage of women older than 30 years was higher than the 
Croatian average age of parturient women (40.4% in 2008) [28]. No data on the prevalence 
of chronic conditions among women of childbearing-age was available for Croatia, but data 
for the US report 9.9% of women of childbearing-age with a chronic condition [29].  Twenty 
seven percent of women were smoking, which is in agreement with Croatian statistics 
(approximately 30% of smokers among women) [30]. Approximately 40 % of advised women 
were in their first pregnancy which is a slightly lower rate as compared with the Croatian 
average (48% of first pregnancies) [31]. 
Overall, clinical pharmacologists’ risk estimation was in agreement with the FDA risk 
classification system in only 28% of consulted cases. Although 34% of patients were 
exposed to FDA category DX drugs, high risk exposure according to a clinical 
pharmacologist’s assessment was recorded in only 9% of patients (NRS 4 and 5). 
Percentages of A-X risk assessments by FDA risk classification and a clinical pharmacologist 
are shown in Chart 1. The found rate of disagreement in estimation of risk of pregnancy-
related drug exposures in our study (72%) was higher than recorded in one similar study that 
compared the differences in advice on drug safety in pregnancy between product 
monographs and five Drug Information Centres in Norway. The authors found a 47% 
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difference in advices given on drug safety in pregnancy between these two sources of 
information, with information from the product monographs being significantly more restrictive 
[17]. This could be explained by the possibility of more accurate risk estimation in our study 
due to available data on all relevant risk factors, timing and dosage of drug exposure. 
Furthermore, the mentioned study did not include pregnancy outcomes. Subsequently, the 
question may be raised if the less restrictive advice on drug safety in pregnancy was an 
understatement of risk and possibly resulted in more adverse pregnancy outcomes.   
Due to known difficulties associated with assessments of the benefits and risks of drug 
therapy during pregnancy, there is a concern among prescribers about underestimating the 
risks of drug exposure especially during early pregnancy. The exclusive use of the FDA 
classification system could lead to overestimation of the risk which may result in unnecessary 
withholding of beneficial therapy or in the termination of otherwise wanted pregnancies. This 
thesis is supported by our own experience; pregnant women are in some cases referred from 
other specialists for consultation with the aim to ease the decision for therapy cessation or 
patients’ decision for pregnancy termination.  
Despite the fact that in 72% of women included in our study the risk estimation was lower as 
compared to the FDA risk classification system, adverse pregnancy outcomes in this group 
were not more frequent when compared with the group with the same risk estimation (7.9% 
vs. 11.8%, respectively; p=0.211; and 12.7% vs. 20.0% in FDA DX group, p=0.304). 
The potential impact of differences in risk estimations can be illustrated by evaluating the 
distinctions in risk assessments within the FDA category X. The clinical pharmacologists’ risk 
assessment was in agreement with the FDA risk classification system for only 21 out of 150 
women with FDA category X exposure. In all other cases the risk estimation was lower. In 
everyday clinical practice, this difference could mean a significant decrease in numbers of 
potentially unnecessary induced pregnancy terminations. Indeed, after obtaining the clinical 
pharmacologists’ expert opinion, only 10 out of 78 women with available outcomes (13%) 
exposed to FDA category X drugs considered the risk high enough to undertake an induced 
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pregnancy termination. We can only assume that this number would be higher without the 
risk reassessment done by a clinical pharmacologist.   
A good example is the use of oral contraceptives in early pregnancy. Although oral 
contraceptives are categorized as FDA category X drugs, available evidence does not 
support such high risk estimation for exposure during early pregnancy. There is no firm 
evidence linking oral contraceptives with any fetal anomalies except possible masculinization 
of the female external genitalia. Exposure after 8 weeks of gestation would presumably be 
required for this effect to occur [32]. Out of 64 pregnancies with documented exposure to oral 
contraceptives during the 1st trimester of pregnancy with available outcomes, there were 52 
pregnancies (81%) that resulted in delivery of a healthy child, 5 spontaneous abortions (8%), 
4 induced abortions, 1 pregnancy complication (1.6%; a case of a preterm delivery) and 2 
congenital anomalies (1 major and 1 minor congenital malformation). Both the rate of 
congenital malformations and the rate of spontaneous abortions in women exposed to oral 
contraceptives during the first trimester in our study were within expected rates (3% and 8%, 
respectively).  
The overall rate of congenital malformations in our study was 0.6% (3/465) which is lower 
than the expected rate of congenital malformations within general population of pregnant 
women in Europe (2.3%) acording to data from the European Surveillance of Congenital 
Anomalies [23]. We have no obvious explanation for such a low rate of congenital 
malformation recorded in our study. The rate of spontaneous abortions in our study was 
6.2% (32/465), which is as well lower than the expected rates of 10-15% [34,35]. The rate of 
spontaneous abortions in Croatia is 15.9% [36]. This finding could be explained with the fact 
that most women were referred to us during the 2nd or 3rd month of pregnancy at a time 
point when some of the spontaneous abortions might have already occured. The rate of 
women with previously legal abortion (9%) was also lower as compared with the general 
population (19%) [35] . This could likely be attributed to underreporting due to unwillingness 
to provide information on previous induced abortions.  
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We assessed the strength of association between both the clinical pharmacologists’ risk 
assessment and the FDA risk categorization, and adverse pregnancy outcomes. Risk 
estimation by a clinical pharmacologist was a better predictor for adverse pregnancy 
outcomes when compared to the FDA risk classification. Despite the mentioned limitations of 
the FDA risk classification system, our study results confirmed its general usefulness in risk 
estimation of pregnancy-related drug exposures. Hence with large numbers of false positives 
and few false negatives, the positive predictive values for adverse pregnancy outcomes were 
low; 14% for the FDA DX (or NRS 4 and 5) classification and 25% for the high risk estimation 
by a clinical pharmacologist (NRS 4 and 5). This means that 14% of women exposed to FDA 
DX drugs during pregnancy will actually have an adverse pregnancy outcome, as well as 
25% of women exposed to drugs classified by a clinical pharmacologist as being hazardous 
(NRS 4 and 5). The negative predictive value for adverse pregnancy outcome was similar 
between both methods of risk classification (94% vs. 92%, respectively), which means that 
94% and 92% of women classified as being exposed to lower-risk drugs will actually not 
have an adverse pregnancy outcome. Due to lack of data from prospective controlled 
studies, it is rarely possible to precisely assess the risks of medication use during pregnancy, 
thus the positive predictive value of any available method for risk estimation of pregnancy-
related drug exposure is expected to be low. From a legal and ethical point of view, it is often 
safer for drug manufacturers and prescribers to overestimate than underestimate potential 
risks. Nevertheless, women must receive accurate and updated information, as unrealistic 
perception of risk may lead to unnecessary terminations of otherwise wanted pregnancies or 
inadequate treatment of maternal disease. 
Other already established risk factors that were confirmed as significantly associated with the 
occurrence of adverse pregnancy outcomes in our study were: age [37], concomitant chronic 
disease [38,39], history of previous pregnancies and number of previous pregnancies [40].  
The most reliable information on drug safety in pregnancy is derived from large population 
based pregnancy registries, like the Norwegian [41] or Swedish Medical Birth Register [42] 
which includes data on practically all deliveries in Sweden. Although the most important 
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advantage of such databases is their size, there are some limitations: reporting bias 
(underreporting of drug use, interviewer’s lack of interest to collect all information, etc.), no 
precise information on dosage and timing of drug use and lack of accurate data on 
underlying diseases. The most important advantage of our study are accurate information on 
the drug dosage and timing of drug exposure, data on confounders, and a low reporting bias 
regarding medication use since the women were referred specifically for that reason.  The 
limitations are the small sample size and a large number of lost to follow-up.  
To the best of our knowledge, this is the first study to examine differences between the FDA 
risk classification and risk assessment done by a clinical pharmacologist (or another expert) 
that included pregnancy outcomes of advised women.  
Consequently, better positive predictive value for adverse pregnancy outcomes of a clinical 
pharmacologists’ risk assessment as compared to the sole use of the FDA risk classification 
system, suggests the important role of a trained expert as a corrector of drug classification 
systems and in providing reliable information for other prescribers as well as pregnant 
women, thus contributing to better resolution of numerous safety issues of drug therapy 
during pregnancy.  
In conclusion, assessing risk of pregnancy-related drug exposure is time consuming and 
requires good knowledge of drug pharmacokinetics and pharmacodynamics, epidemiology, 
teratology as well as training and experience in critical assessment of published data. Clinical 
pharmacologists who have undergone rigorous medical training are ideally placed to consult 
on administration of medicines in pregnant women, thus making the prescribing of treatments 
in that patient category substantially safer and more rational.   
 17
Acknowledgements 
This study did not receive external funding. We acknowledge the help of our nurses Ana 
Anđelić and Marijana Križic-Erceg.  
 18
Conflict of Interests 
The authors declare no conflicts of interest. 
 
 19
References 
1. Oakley GP Jr (1986) Frequency of human congenital malformations. Clin Perinatol 
13:545-54 
2. Koren G (1994) Maternal-fetal toxicology: a clinician’s guide. Marcel Dekker Inc, New York 
3. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL (2000) Prescription of 
drugs during pregnancy in France. Lancet 356:1735-6. doi:10.1016/S0140-6736(00)03209-8  
4. Haramburu F, Miremont G, Moride Y, Gomez MP, Douchet P, Douet C (1995) Drug 
prescription during pregnancy: a cohort study. Pharmacoepidemiol Drug Safety;4:74 
5. Henry A, Crowther C (2000) Patterns of medication use during, and prior to pregnancy: the 
MAP sudy. Aus NZ J Obstet Gynaecol 40:165-72 
6. Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, Fraser W, Olatunbosun O, 
Wen SW (2008) Maternal characteristics associated with pregnancy exposure to FDA 
category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 
17(3):270-7. doi: 10.1002/pds.1538   
7. Webster WS, Freeman JA (2001) Is this drug safe in pregnancy? Reprod 
Toxicol15(6):619-29. doi doi:10.1016/S0890-6238(01)00185-X 
8. Boothby LA, Doering PL (2001) FDA labeling system for drugs in pregnancy. Ann 
Pharmacother 35(11):1485-9 
9. Addis A, Magrini N, Mastroiacovo P (2001) Drug use during pregnancy. Lancet 357:800. 
doi: doi:10.1016/S0140-6736(05)71221-6  
10. Addis A, Sharabi S, Bonati M (2000) Risk classification systems for drug use during 
pregnancy: are they a reliable source of information? Drug Saf 23(3):245-53 
11. Feibus KB (2008) FDA’s proposed rule for pregnancy and lactation labelling: improving 
maternal child health through well-informed medicine use. J Med Toxicol;4(4):284-8 
12. Bencarić L (2009). Registar Lijekova u Hrvatskoj.Udruga poslodavaca u zdravstvu, 
Zagreb 
13. Vrhovac B et al. (2007).Farmakoterapijski priručnik. Medicinska naklada, Zagreb 
14. http://www.entis-org.com/en/aboutus.php. Accessed June 2 2010 
 20
15. http://www.otispregnancy.org/goals-and-mission-s13030. Accessed June 2 2010 
16. ADEC: Australian Drug Evaluation Committee (1996) Medicines in Pregnancy - An 
Australian Categorisation of Risk of Drug Use in Pregnancy. Australian Government 
Publishing Service, Canberra, Australia 
17. Widnes F, Sofia K, Schjott J (2008) Advice on Drug Safety in Pregnancy: Are there 
Differences between Commonly Used Sources of Information? Drug Safety 31(9):799-806 
18. British Medical Association & Royal Pharmaceutical Society of Great Britain (2009) 
British National Formulary. BMJ Group and RPS Publishing, London 
19. American Society of Health-System Pharmacists (2008) AHFS Drug Information. 
American Society of Health-System Pharmacists, Bethesda 
20. Briggs DD (2008) Drugs in pregnancy and lactation. Lippincot Williams Wilkins, 
Philadelphia 
21. Micromedex® Healthcare Series Vol. 144 expires 6/2010 
22. www.ncbi.nlm.nih.gov/pubmed/ 
23. Sannerstedt R, Lundborg P, Danielsson BR, Kihlstrom I, Alvan G, Prame B, Ridley E 
(1996) Drugs during pregnancy: an issue of risk classification and information to prescribers. 
Drug Saf 14:69-77 
24. Buhimschi CS, Weiner CP (2009) Medications in Pregnancy and Lactation: part 1. 
Teratology. Obstet Gynecol 113(1):166-88 
25. Lee E, Maneno MK, Smith L, Wiess SR, Zuckerman IH, Wutoh AK, Xue Z (2006) 
National patterns of medication use during preganancy. Pharmacoepidemiol Drug Saf 
15(8):537-45. doi: 10.1002/pds.1241 
26. Culig J, Leppee M, Stimac D, Kuvacic I, Pulanic-Klepac T, Herman R, Tuckar N, 
Podobnik M, Klobucar A, Matesa S, Polic-Vizintin M, Damic A (2007) [Cross-sectional study 
of drug use in pregnancy]. Lijec Vjesn 129:253-259 
27. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, 
McPhillips H, Roblin D, Smith DH, Yood MU, Platt R, H Gurwitz J (2006) Use of prescription 
 21
medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol 
Drug Saf 15(8):546-54. doi: 10.1002/pds.1235   
28. http://www.dzs.hr/Hrv_Eng/menandwomen/men_and_women_2009.pdf. Accessed 2 
June 2010 
29. P. Adams, G. Hendershot and M. Marano (1999) Current estimates from the National 
Health Interview Survey. Vital Health Statistics 10: 83–84 
30. Kovacić L, Gazdek D, Samardzić S (2007) [Croatian health survey: cigarette smoking]. 
Acta Med Croatica 61(3):281-5 
31. http://www.hzjz.hr/publikacije/porodi2008.pdf. Accessed 2 June 2010 
32. Briggs GG, Freeman RK, Yaffe JS (2008) Drugs in Pregnancy and Lactation, Lippincott 
Williams & Willkins, Philadelphia  
33. http://www.eurocat-
network.eu/prevdata/results.aspx?title=A1&allanom=false&allregf=true&allrega=falseundefin
ed&winx=1256&winy=894. Accessed 2 June 2010 
34. Nybo Andersen AM, Wohlfart J, Christens P, Olsen J, Melbye M (2000) Maternal age and 
fetal loss: population based register linkage study. BMJ 320:1708-1712 
35. de La Rochebrochard E, Thonneau P (2002) Paternal age and maternal age are risk 
factors for miscarriage; results of a multicentre European study. Hum Reprod 17(6):1649-56 
36. http://www.hzjz.hr/publikacije/prekidi_2008.pdf. Accessed 2 June 2010 
37. Delbaere I, Verstraelen H, Goetgeluk S, Martens G, De Backer G, Temmerman M (2007) 
Pregnancy outcome in primiparae of advanced maternal age. Eur J Obstet Gynecol Reprod 
Biol 135(1):41-6. doi:10.1016/j.ejogrb.2006.10.030 
38. Khairy P, Ouyang DW, Fernandes, SM, Lee-Parritz, A, Economy KE, Landzberg MJ 
(2006) Pregnancy outcomes in women with congenital heart disease. Circulation 113:517-24. 
doi: 10.1161/CIRCULATIONAHA.105.589655 
39. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C (2008) Pregnancy outcomes in 
women with epilepsy: A systematic review and meta-analysis of published pregnancy 
registries and cohorts. Epilepsy Res 81(1):1-13. doi:10.1016/j.eplepsyres.2008.04.022  
 22
40. Bai J, Wong FWS, Bauman A, Mohsin M (2002) Parity and pregnancy outcomes. 
American Journal of Obstetrics and Gynecology 2002; 186 (2):274-78. 
doi:10.1067/mob.2002.119639 
41. Engeland A, Bramness JG, Dalveit AK, Ronning M, Skurtveit S, Furu K (2008) 
Prescription drug use among fathers and mothers before and during pregnancy. A 
population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin 
Pharmacol 65(5):653-60. doi: 10.1111/j.1365-2125.2008.03102.x. 
42.http://www.socialstyrelsen.se/register/halsodataregister/medicinskafodelseregistret/inengli
sh. Accessed 2 June 2010 
43. Samrén EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, 
Deichl AW, Gaily E, Granström ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D 
(1997) Maternal use of antiepileptic drugs and the risk ofmajor congenital malformations: 
a joint European prospective study of human teratogenesis associated 
with maternal epilepsy. Epilepsia;38:981–90. 
44. Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, Gallo C 
(2002) Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol; 
99:35-40. 
 
 
 
 
 
 
 
 
 
 
 23
Table 1. Comparison between risk classifications (FDA vrs. clinical pharmacologists' risk 
assessment). 
 
Risk categorization FDA Clinical pharmacologist's risk 
assessment FDA Numeric scale 
A  1 Controlled studies show no 
risk. Adequate, well-controlled 
studies in pregnant women 
have failed to demonstrate a 
risk to the fetus. 
No risk to the fetus according 
to available data (e.g. 
acetaminophen).  
B  2 No evidence of risk in humans. 
Either animal study shows risk, 
but human findings do not, or if 
no adequate human studies 
have been done, animal 
findings are negative. 
Risk to the fetus unlikely 
according to available data 
(e.g. penicillins, 
cephalosporins). 
C  3 Risk cannot be ruled out. 
Human studies are lacking, 
and animal studies are either 
positive for fetal risk or lacking. 
However, potential benefits 
may justify potential risk. 
Risk cannot be excluded 
according to available data 
(e.g. doxycycline in I trimester) 
or not enough data available 
for accurate risk assessment 
(e.g. tianeptine). 
D  4 Positive evidence of risk. 
Investigational or 
postmarketing data show risk 
to the fetus. Nevertheless, 
potential benefits may 
outweigh the potential risk.  
Risk to the fetus significantly 
higher than in general 
population according to 
available data; e.g. expected 
rate of  congenital 
malformations with sodium 
valproate aproximately 9% 
[43].  
X  5 Contraindicated in pregnancy. 
Studies in animals or humans 
or investigational or 
postmarketing reports have 
shown fetal risk, which clearly 
outweighs any possible benefit 
to the patient.  
Risk to the fetus very likely; 
e.g. approximately 40% 
negative pregnancy outcomes 
with warfarin [44]. 
Contraindicated drugs in 
pregnancy.  
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Table 2. Patient’s demographic and referral characteristics (N=1144), and data on 
pregnancy-related drug exposure.  
 
 Mean (range) N (%) 
ALL PATIENTS  
Maternal Age (yrs) (N=1133) 29.9 (±5.50, 16-47)  
Smoking (N=1116)  305 (27.3) 
Consultation on: (N=1143)   
Exposure to drugs during this pregnancy  1076 (94.1) 
Therapy planning during this pregnancy   22 (1.9) 
Therapy planning for future pregnancy   19 (1.7) 
Diagnostic procedure during pregnancy  13 (1.4) 
Drugs taken by the partner at the time of 
conception 
 7 (0.6) 
Other problems*  4 (0.3) 
Pregnancy planning, partner on chronic drug 
therapy 
 2 (0.2) 
Consultation not possible due to inadequate data†  1 (0.1) 
First pregnancy (N=1059)  602 (56.8)  
- Previous spontaneous abortions  81/602 (13.5) 
PATIENTS ADVISED ON DRUG EXPOSURE DURING PREGNANCY (N=1076) 
Pregnancy trimester at the time of consultation 
(N=967) 
Mean (Std.Dev., 
Range) 
N (%) 
I  823 (85.1) 
II  138 (14.3) 
III  6 (0.6) 
Concomitant disease present (N=1073)  555 (51.7) 
Average number of drugs taken 2.1 (±1.29, 1-9)  
Monotherapy  492 (45.7) 
≥2 drugs  584 (54.3) 
Indication for drug prescription:   
Acute illness   480 (44.8) 
Chronic illness  436 (40.7) 
Other indication  120 (11.2) 
Acute and chronic illness  22 (2.1) 
Acute illness, other indication  10 (0.9) 
Chronic illness, other indication  3 (0.3) 
Time of drug exposure: (N=2195)   
Before pregnancy  31 (1.4) 
I trimester  2084 (94.9) 
II trimester  7 (0.3) 
III trimester  3 (0.1) 
I, II trimester  68 (3.1) 
I, II, III trimester  2 (0.1) 
FDA category drug exposure/NRS   
A/1  86 (7.9) 
B/2  445 (41.2) 
C/3  603 (56.0) 
D/4  330 (30.5) 
X/5  150 (13.9) 
NC‡  57 (5.4) 
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FDA risk category drug exposure to at least§:    
A/1  17 (1.6) 
B/2  173 (16.2) 
C/3  410 (38.5) 
D/4  316 (29.6) 
X/5  150 (14.1) 
Mean point value at the numeric scale 3.4 (±0.96)  
Clincal pharmacologists' risk asesment    
A/1  31 (2.9) 
B/2  822 (77.1) 
C/3  121 (11.4) 
D/4  72 (6.8) 
X/5  20 (1.9) 
Mean point value at the numeric scale 2.3 (±0.71)  
Available pregnancy outcomes (N=516)   
Normal  428 (82.9) 
Arteficial abortion  46 (8.9) 
Spontaneus abortion   31 (6.0) 
Other complications  8 (1.6) 
Major malformation  1 (0.2) 
Minor malformations  2 (0.4) 
* 1 pt- inhalation of xylene gas; 2 pt- exposition to smallpox; 3 pt- exposition to organic 
solvents; 4 pt- exposition to a person who reacently underwent therapy with radioactive 
iodine 
† the patient didn't know which medication she was taking & no medical documentation was 
available 
‡ NC- drugs not categorized by FDA 
§ 10 FDA NC drugs excluded 
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Table 3. Differences in risk estimation. 
 
 N (%) 
FDA CDX 876 (82.2) 
Clinical pharmacologists risk estimation  
Same risk estimation 297 (27.8) 
Lower risk estimation 770 (72.2) 
Clinical pharmacologists risk estimation by FDA category:  
FDA C  
Same risk estimation 37 (9.0) 
Lower risk estimation 373 (91.0) 
Mean point difference; mean (±Std.Dev., range) 0.9 (±0.32, 0-2) 
FDA D  
Same risk estimation 54 (17.1) 
Lower risk estimation 262 (82.9) 
Mean point difference; mean (±Std.Dev., range) 1.5 (±0.78, 0-3) 
FDA X  
Same risk estimation 21 (14.0) 
Lower risk estimation 129 (86.0) 
Mean point difference; mean (±Std.Dev., range) 2.2 (±1.1, 0-4) 
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Table 4. Risk factors associated with adverse pregnancy outcomes.  
 
 OR ±95% CI p-value 
FDA risk classification (numeric scale) 1.52 1.09-2.13 0.014 
FDA category DX 2.71 1.39-5.24 0.002 
Clinical pharmacologist risk assessment 
(numeric scale) 
2.11 1.46-3.05 <0.001 
Clinical pharmacologists' risk assessment (4 
and 5; corresponding to FDA DX) 
4.05 1.76-9.32 0.002 
Number of drug exposures 1.20 0.95-1.51 0.118 
Age  1.10 1.14-1.18 <0.001 
Age ≥ 30 years 3.87 1.81-8.30 <0.001 
Previous pregnancy 2.38 1.16-4.85 0.014 
Number of previous pregnancies 1.58 1.15-2.18 0.005 
Previous history of spontaneous abortion  1.54 0.58-4.06 0.409 
Number of spontaneous abortions 6.38 1.09-37.39 0.033 
Concomitant disease present 2.98 1.46-6.08 0.002 
Smoking 1.03 0.49-2.19 0.920 
OR- odds ratio; CI- confidence intervals 
 
 28
Chart 1. Percentages of A-X risk assessments by the FDA risk classification and a clinical 
pharmacologist (NRS; numeric rating scale). 
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